Latest News
News from the FDA/CDC
FDA OKs Next-Gen Cologuard Test for CRC Screening
Cologuard Plus tests for three novel methylated DNA markers and fecal hemoglobin.
Conference Coverage
IMRT vs Proton Therapy for Early Prostate Cancer?
The results of a new trial demonstrate ‘equivalent outcomes, with superb cancer control rates and extremely low toxicity from both treatments.’
Conference Coverage
NCCRT Confirmed as Best Approach in Locally Advanced, Resectable ESCC
Researchers compred neoadjuvant concurrent chemoradiotherapy with adjuvant sequential chemoradiotherapy (ASCRT) in locally advanced esophageal...
Conference Coverage
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.
Conference Coverage
Daratumumab Quadruplet Supported Transplant-Ineligible MM
A phase-3 study showed that adding daratumumab to VRd yields a primary endpoint of MRD negativity in patients newly diagnosed with myeloma.
From the Journals
Dermatomyositis Cancer Screening Guidelines Get Real-World Validation
Most of the cancers were detected using standard age- and sex-based cancer screenings, suggesting the potential for overscreening in this...
Latest News
Millennial Clinicians Face Pay Disparities by Specialty, Other Factors
“Procedures are reimbursed too high, while very little value is placed on primary care.”
Feature
‘Cancer Doesn’t Wait’: How Prior Authorization Harms Care
Despite the large tumor, nestled in a sensitive area, a Boston-based radiation oncologist could envision a bright future for her patient.
Latest News
Race Adjustments in Algorithms Boost CRC Risk Prediction
“Removing race from colorectal screening predictors could reduce the number of Black patients recommended for screening.”
Latest News
A Few Rural Towns Are Bucking the Trend and Building New Hospitals
New full-service hospitals with inpatient beds are rare in rural America, where declining population has spurred decades of downsizing and...
Feature
Pfizer’s Withdrawal of SCD Drug Raises Questions
The worldwide withdrawal by Pfizer of its sickle cell disease drug voxelotor has hematologists wondering why and racing to inform their patients...